Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 4Ovarian Neoplasms 2Lymphoma 2Neoplasms 1Neoplasm Metastasis 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 36Nivolumab 16Cyclophosphamide 12atezolizumab 8Docetaxel 8Magnetic Resonance Spectroscopy 7Paclitaxel 6Everolimus 6spartalizumab 5fludarabine 5durvalumab 5Specimen Handling 5Ipilimumab 5cabozantinib 4avelumab 4Trastuzumab 4Radiotherapy 4Radiosurgery 4Oxaliplatin 4Leucovorin 4temsirolimus 3pazopanib 3aldesleukin 3Taxes 3Sunitinib 3Psychiatric Rehabilitation 3Interleukin-2 3Immune Checkpoint Inhibitors 3Gemcitabine 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × valspodar × Breast × Clear all
NCT00001383 2008-03-04

A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
52 enrolled
BreastGenitourinaryGynecologicLymphoid

Breast Neoplasms, Carcinoma, Renal Cell, Lymphoma, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡